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ABC transporters constitute a family of evolutionarily highly conserved multispan proteins that mediate the translocation of defined substrates
across membrane barriers. Evidence has accumulated during the past years to suggest that a subgroup of 12 structurally related “full-size”
transporters, referred to as ABC A-subfamily transporters, mediates the transport of a variety of physiologic lipid compounds. The emerging
importance of ABC A-transporters in human disease is reflected by the fact that as yet four members of this protein family (ABCA1, ABCA3,
ABCR/ABCA4, ABCA12) have been causatively linked to completely unrelated groups of monogenetic disorders including familial high-density
lipoprotein (HDL) deficiency, neonatal surfactant deficiency, degenerative retinopathies and congenital keratinization disorders. Although the
biological function of the remaining 8 ABC A-transporters currently awaits clarification, they represent promising candidate genes for a
presumably equally heterogenous group of Mendelian diseases associated with perturbed cellular lipid transport. This review summarizes our
current knowledge on the role of ABC A-subfamily transporters in physiology and disease and explores clinical entities which may be potentially
associated with dysfunctional members of this gene subfamily.
© 2006 Elsevier B.V. All rights reserved.Keywords: ABC transporter; Lipid; Atherosclerosis; Retina; Surfactant; Ichthyosis1. Introduction
ATP-binding cassette (ABC) transporters constitute one of
the largest known superfamilies of proteins [1]. These
evolutionary highly conserved multispan transmembrane mole-
cules use the energy of ATP hydrolysis to translocate a broad
spectrum of molecules across the cell membrane. Substrates that
are transported by ABC molecules include lipids, peptides,
amino acids, carbohydrates, vitamins, ions, glucuronide and
glutathione conjugates, and xenobiotics [1,2]. In eukaryotes,
ABC transporters are located in the plasma membrane, in the
membranes of intracellular compartments such as the Golgi,
endosome, multivesicular bodies, endoplasmic reticulum,
peroxisome, and in mitochondria. To date, 48 members of the⁎ Corresponding author. Tel.: +49 0621 383 4012; fax: +49 0621 383 3819.
E-mail address: wolfgang.kaminski@ikc.ma.uni-heidelberg.de
(W.E. Kaminski).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.01.011human family of ABC transporters have been identified which,
based on their structural relatedness, are subdivided into 7
families, designated ABC A–G [1].
Functional ABC transporters show a common global
organization. So-called full-size ABC transporters are typically
composed of two tandemly linked functional units [3], each
consisting of an ATP binding cassette and a transmembrane
domain complex. Alternatively, they can form homo- or
heterodimers which consist of two half-size transporters that
are encoded by distinct genes [4]. Evidence has accumulated to
suggest that ABC transporters exert their functions as
membrane associated multiunit complexes. Examples include
the ABC transporter ABCC8 (SUR1) which is functionally
associated with the K+ channel KIR6.1 and a potassium-
sensitive Ca2+-channel [5,6]. Moreover, the transporter CFTR
(ABCC7) binds syntaxin 1A, a member of the syntaxin family
of membrane fusion regulators [7], a sodium channel [8] and the
endocytic adaptor complex AP-2 [9]. It is thus conceivable that
full-size ABC transporters, as large components of membrane
associated multiunit complexes, are not necessarily restricted to
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of biologic activities depending on the specific assembly of the
functional complex and the biologic activities of their
interaction partners.
2. Structural and evolutionary features of human ABC
A-subclass transporters
ABCA1 and ABCA2 (formerly known as ABC1 and
ABC2, respectively), the prototypic members of the ABC A-
subfamily, were initially co-identified by Luciani et al. [10] in
the mouse. Throughout the past decade, 10 additional
functional genes were discovered. Based on their common
structural features, which set them apart from other ABC
transporters, they were categorized into a distinct subgroup—
the ABC A-subfamily [1]. The known 12 human ABC A-
transporters have been denoted ABCA1–ABCA13. The
current nomenclature is inconsistent in that since no
functional human “ABCA11” gene exists (a designation that
has originally been erroneously assigned to a pseudogene).
Structurally, all ABC A-transporters are full-size transporters
that range from 1543 to 5058 amino acids (aa) in size. A
synopsis of their biological features is shown in Table 1. With
the exception of ABCR, which is selectively expressed in the
retina, and ABCA13, whose expression appears to be limited
to a small number of organs, ABC A-transporters have broad
tissue-specificity.
Pairwise comparison of the amino acid sequences of all
known 12 human ABC A-subfamily members reveals
homologies ranging from 28% (ABCA8/ABCA12) to 72%
(ABCA8/ABCA9) (Table 2). Phylogenetic analysis suggests
that all ABC A-subclass genes have evolved from a
primordial ancestor gene and were subsequently dispersed
across the genome (Fig. 1) [1]. Of note, the transporters
ABCA5, ABCA6, ABCA8, ABCA9, and ABCA10 share
strikingly high overall amino acid sequence homologies but
differ significantly from other ABC A-subfamily members.
Based on this and the fact that their genes form a compactTable 1
Biological features of ABC A-transporters
Gene GenBank
accession no.
Chrom.
localization
Gene
size (kb)
Exons
ABCA1 NM_005502 9q31.1 147 50
ABCA2 NM_001606 9q34.3 21 48
ABCA3 NM_001089 16p13.3 65 33
ABCA4 NM_000350 1p22.1 128 50
ABCA5 NM_018672 17q24.3 69 38
ABCA6 NM_080284 17q24.2–3 63 39
ABCA7 NM_019112 19p13.3 24 46
ABCA8 NM_007168 17q24.2 88 38
ABCA9 NM_080283 17q24.2 86 39
ABCA10 NM_080282 17q24.3 97 40
ABCA12 NM_173076 2q35 207 53
ABCA13 NM_152701 7p12.3 449 60
Accession numbers refer to the NCBI GenBank, chromsomal localizations to the U
were determined on the basis of the respective complete cDNAs using the UCSC Ge
SIM4 alignments, respectively. Amino acid numbers and molecular weights were cal
“ABCA11” gene; nr, not reported.cluster on chromosome 17q, it has been suggested that these
five transporters represent a separate subgroup within the A-
subfamily (“ABCA6-like transporters”) [11,12].
3. ABC A-subclass transporters causing inherited diseases
In the 1990s, considerable efforts have been made to study
the role of ABC transporters in multidrug resistance in the
context of tumor cell therapy. However, the bona fide biological
functions of most known ABC transporters remained and still
remain unclear. In recent years, a series of groundbreaking
studies has dramatically expanded our knowledge of the role of
ABC molecules in physiology and disease and has led to the
systematic identification of all members of the human ABC
transporter gene family.
Assessment of the biological role of full-size ABC trans-
porters is a difficult task because of the complex architecture of
these large molecules, their strategic position between two
compartments that are separated by lipid bilayers and the fact
that they appear to operate as part of membrane bound
multifunction complexes. Most valuable insights into their
physiologic functions come from loss of function scenarios as
they occur in human monogenetic diseases and genetically
modified null mutant mice. To date, loss of function mutations
in 14 ABC transporters have been causatively linked to
Mendelian disorders (Table 3). Interestingly, among human
ABC transporters outside the A-subfamily a striking tropism
can be observed for diseases that manifest with defective
exocrine/endocrine function in the liver–pancreas system.
These include disorders associated with dysfunctional bile
secretion (progressive familial intrahepatic cholestasis types 2
and 3, and Dubin–Johnson syndrome caused by defective
ABCB4, ABCB11, and ABCC2, respectively), cystic fibrosis
(CFTR/ABCC7) and familial hyperinsulinism (ABCC8) [13–
15]. Moreover, the ABC C-subfamily transporter ABCC6,
mutations of which mainly cause a skin phenotype known as
pseudoxanthoma elasticum, is strongly expressed in the liver
and calcifications in the pancreas have also been reported [16].Alt. spliced
mRNAs
Cholesterol
responsiveness
Amino
acids
Molecular
weight (kDa)
nr + 2261 254
nr + 2436 270
nr ? 1704 191
nr − 2273 256
nr ? 1642 187
1 + 1617 184
2 + 2146 235
nr ? 1581 179
3 + 1624 184
4 + 1543 176
2 ? 2595 293
5 ? 5058 576
CSC Genome browser (http://genome.ucsc.edu). Gene sizes and exon numbers
nome browser (NCBI/UCSC Build 35, May 2004) and confirmed by BLAT and
culated with the EMBOSS program “pepstats”. Note the absence of a functional
Table 2
Pairwise amino acid sequence similarities/identities (%) between human ABC A-transporters
CDS ABCA1 ABCA2 ABCA3 ABCA4 ABCA5 ABCA6 ABCA7 ABCA8 ABCA9 ABCA10 ABCA12 ABCA13
ABCA1 100/100
ABCA2 54/46 100/100
ABCA3 51/41 51/41 100/100
ABCA4 60/52 50/40 49/39 100/100
ABCA5 41/31 42/31 41/30 41/30 100/100
ABCA6 43/31 42/31 40/29 41/31 53/43 100/100
ABCA7 63/54 50/41 49/39 58/49 40/29 39/29 100/100
ABCA8 42/31 43/32 42/32 41/30 53/42 67/60 41/31 100/100
ABCA9 41/31 41/31 43/33 41/30 53/43 68/60 42/32 78/72 100/100
ABCA10 42/31 42/32 41/30 41/29 54/44 70/63 41/29 69/62 71/63 100/100
ABCA12 47/36 44/34 47/35 46/35 41/28 39/28 47/36 40/28 40/28 41/30 100/100
ABCA13 47/36 44/35 45/35 46/35 40/30 40/30 45/36 41/31 39/29 40/30 47/38 100/100
Percentages of overall amino acid sequence similarities and identities were assessed utilizing the GAP software (GCG, HUSAR, DKFZ, Heidelberg, Germany), CDS,
coding sequence.
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have been extensively reviewed by others (for reference see
[13–15,17]). In this article, we will primarily focus on the
biology of A-subclass ABC transporters and their various
implications in disease.
3.1. ABCA1-familial HDL-deficiency syndromes and
atherogenesis
ABCA1 is the defining member of the A-subclass of ABC
proteins. It is expressed in a multitude of human organs with
highest expression levels in placenta, liver, lung, adrenal
glands and fetal tissues [18]. ABCA1 is upregulated by
cholesterol influx in macrophages and suppressed by HDL3
mediated cholesterol efflux [18]—a characteristic feature that
it shares with other ABC A-subfamily transporters (Table 1).
The human cDNA codes for a 2261-amino acid polypeptide
with a molecular weight of 220 kDa [18,19]. ABCA1 shows
highest amino acid homology with ABCA7 (54%) [20] and
the retina-specific ABCA4 (52%), respectively [21,22]. After
the identification of ABCA1 in 1994 [10], only little was
known about the biologic function of ABCA1 for quite some
time. The major breakthrough came 5 years later when we
and others discovered that mutations in the human ABCA1
gene are the underlying molecular defect in familial high-
density lipoprotein (HDL)-deficiency syndromes (Tangier
disease, TD) which identified ABCA1 as a major regulator
of HDL metabolism [23–25]. TD is a rare autosomal
recessive disorder of lipid metabolism characterized by almost
complete absence of plasma HDL and the accumulation of
cholesteryl esters in the cells of the reticulo-endothelial
system leading to splenomegaly and enlargement of tonsils
and lymph nodes [26]. Consistent with the finding that
mutations in ABCA1 cause an HDL deficiency phenotype in
humans, we found that mice lacking functional ABCA1
exhibit plasma lipid alterations that are concordant with those
observed in TD [27].
More than 50mutationswithin the coding region of the human
ABCA1 gene have thus far been identified (for reference see The
Human Gene Mutation Database, http://www.hgmd.cf.ac.uk).When looking at the topological distribution of known
mutations within the ABCA1 protein product, two findings
are of note. First, mutations within the ABCA1 gene appear to
occur in clusters. Major mutation clusters can be found in the C-
terminal moiety of the first extracellular domain, the N-terminal
ATP binding cassette and the C-terminus. Secondly, mutations
in the first extracellular domain and the C-terminus mutations
are frequently associated with a cardiovascular phenotype. In
contrast, amino acid exchanges in or in the proximity of the N-
terminal ATP binding cassette appear to coincide with
splenomegaly. These observations raise the possibility that
amino acid substitutions within a few selected domains of the
ABCA1 protein may, to a significant degree, determine the type
of clinical presentation. In light of this, one may postulate a
critical function for the C-terminal moiety of the first
extracellular domain and the C-terminus in the development
of the cardiovascular phenotype.
Because TD is a very rare disease, it is uncertain to what
extent allelic variants in the ABCA1 gene affect HDL levels in
the general population. A number of studies have reported
polymorphisms in the coding and non-coding regions of
ABCA1 that are associated with increased risk for cardiovas-
cular disease (CAD) [28–31]. In particular, a recent study in a
large Caucasian cohort suggests that at least 10% of individuals
with low HDL cholesterol are heterozygous for mutations in
ABCA1 and that both mutations and allelic variants in this gene
contribute to HDL levels in the general population [32]. On the
other hand, one dimorphism in the ABCA1 gene, R219K,
appears to exert atheroprotective effects [30]. At this point,
however, it remains unclear whether single allelic variants in the
ABCA1 gene are indeed useful risk predictors in CAD. Since it
is realistic to assume that ABCA1, like other full-size ABC
transporters, functions as component of a membrane associated
higher order functional complex, specific emphasis needs to be
put on genetic variations of the known and potential interaction
partners of this large molecule.
ABCA1 is localized on the plasma membrane and its surface
expression is upregulated in macrophages by cholesterol
loading [27]. In the plasma membrane, ABCA1 is associated
with a Lubrol-detergent resistant raft subfraction [33]. The fact
Fig. 1. Phylogenetic consensus tree and chromosomal dispersion of human ABC A-subfamily transporter genes. Full length amino acid sequences were aligned using
CLUSTALX (http://bips.u-strasbg.fr/fr/Documentation/ClustalX/) and phylogenetic analysis was performed utilizing the PHYLIP software (http://evolution.genetics.
washington.edu/phylip.html). Bootstrap values (%) out of 100 iterations are indicated at each branch point. The chromosomal loci are schematically shown for each
ABC A-subfamily transporter gene (arrowheads). Genomic mapping data for individual genes were updated by BLAT search (http://genome.ucsc.edu/) and may
therefore, in some cases, slightly differ from previously proposed loci. Inset: Schematic representation of the structural organization of ABC A-transporters. Each
family member is typically composed of two transmembrane domains (TMD1, TMD2), each containing six membrane-spanning α-helices (grey shaded barrels) and
two nucleotide binding domains (NBD1, NBD2). Characteristic structural features also include a large extracellular loop between the first and second transmembrane
helix (arrow) and two conserved 80-amino acid segments adjacent to the NBDs (asterisks).
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lysosomes [27,34,35] supports the view that it is a mobile
molecule that may shuttle between the plasma membrane, the
Golgi and the lysosomal compartment as constituent of a
vesicular transport route. Initial studies on the biologic role of
ABCA1 suggested it functions as a translocator of lipids
between the inner and outer plasma membrane [36]. This was
based on experiments showing an increase in cholesterol and
phospholipid export under conditions of forced ABCA1
expression and in ABCA1 deficient cells which characteristi-
cally display the reverse scenario [27]. Moreover, overexpres-
sion experiments suggest that ABCA1 may actively mediate
intracellular cholesterol transport [37]. Intriguingly, studies in
insect Sf9 cells indicated that the ATP turnover of ABCA1occurs at a very low rate whereas nucleotide binding is
sufficient to induce conformational changes in this protein [38].
This is in line with a more recent report which demonstrated that
ATP is hydrolyzed at the nucleotide binding cassettes of
ABCA1 also in mammalian HEK293 cells using vanadate-
induced nucleotide trapping [35,38]. The observed low ATP
turnover suggests that ABCA1 may rather act as a facilitator of
cholesterol/choline-phospholipid export within the cellular lipid
export machinery than exert a genuine translocator function.
However, this issue still needs to be addressed in more detail.
The exact molecular mechanisms by which ABCA1 mediates
the export of lipid compounds from the cell are still unclear. In
this context, the question arises as to which molecular partners
interact with and thus potentially modulate ABCA1 function.
Table 3
Human ABC transporter genes and associated monogenetic disorders
Gene Monogenetic disorder OMIM no.
ABCA1 Tangier disease 205400
Familial hypoapolipoproteinemia 604091
ABCA3 Respiratory distress syndrome (Neonatal
surfactant deficiency)
267450
ABCA4 Stargardt disease 248200
Retinitis pigmentosa 19 601718
Cone rod dystrophy 3 604116
Age-related macular degeneration 153800
ABCA12 Lamellar ichthyosis type 2 (Ichthyosis congenital IIB) 601277
Harlequin ichthyosis (Ichthyosis congenita,
Harlequin fetus type)
242500
ABCB4 Progressive familial intrahepatic cholestasis type 3 602347
ABCB7 X-linked sideroblastosis and anemia 301310
ABCB11 Progressive familial intrahepatic cholestasis type 2 601847
ABCC2 Dubin–Johnson Syndrome 237500
ABCC6 Pseudoxanthoma elasticum 264800
ABCC7 Cystic fibrosis (Mucoviscidosis) 219700
Congenital bilateral absence of the vas deferens 277180
ABCC8 Familial persistent hyperinsulinemic
hypoglycemia of infancy
601820
ABCD1 Adrenoleukodystrophy 300100
ABCG5 β-sitosterolemia 210250
ABCG8 β-sitosterolemia 210250
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syntrophin/utrophin complex that may couple ABCA1 to the F-
actin cytoskeleton [39]. Moreover, ABCA1 function depends
on binding to Fas-associated death domain protein (FADD), an
adaptor molecule involved in death receptor signal transduction
suggesting a potential interlink between ABCA1 and apoptosis
[40].
Macrophages play a key role in the initiation and progression
of atherosclerotic lesions [41]. In the nascent lesion, they
transform into foam cells through the excessive accumulation of
cholesteryl esters. Dysfunctional lipid homeostasis in macro-
phages and foam cells ultimately results in the breakdown of
membrane integrity and cell death. The findings that ABCA1 is
upregulated in human macrophages during sustained uptake of
cholesterol [18,27] and that it facilitates cholesterol export from
the cell early on suggested its implication in foam cell
development and the formation of lesions of atherosclerosis.
Among patients with defective ABCA1 one subgroup
develops premature atherosclerosis, whereas another one
presents predominantly with splenomegaly [26] indicating
differences in macrophage targeting to tissues in ABCA1
deficiency. Recent experiments using chimeric LDLR−/− mice
lacking ABCA1 in their circulating cells demonstrate that the
selective disruption of ABCA1 in circulating cells, in
particular macrophages, impacts macrophage targeting into
the vascular wall and lesion formation in vivo. LDLR−/−
chimeras deficient in ABCA1 develop significantly larger
(60%) and more advanced atherosclerotic lesions compared to
chimeric LDLR−/− mice with functional ABCA1 in hemato-
poietic cells [42]. Importantly, targeted disruption of leukocyte
ABCA1 function in this study did not affect plasma HDL
cholesterol levels. These results provide direct evidence thatleukocyte ABCA1 alone can exert significant anti-atheroscle-
rotic activity independently of plasma HDL levels. They also
indicate that the absence of ABCA1 from only leukocytes is
sufficient to induce aberrant monocyte recruitment into the
spleen identifying ABCA1 as a critical leukocyte factor in the
control of monocyte targeting [42]. The view that macrophage
ABCA1 functions as an important anti-atherosclerotic factor is
supported by another study demonstrating that targeted
inactivation of ABCA1 in macrophages leads to increased
lesion formation and foam cell accumulation in apoE null
mutant mice [43]. A reciprocal approach using ABCA1
overexpressing transgenic apoE null mice revealed that forced
expression of human ABCA1 results in the formation of
smaller, less-complex lesions in apoE knockout mice [44].
Collectively, these in vitro and in vivo findings underscore the
critical role of ABCA1 in macrophage lipid homeostasis and
highlight its significant anti-atherosclerotic activity.
Since the cloning of the ABCA1 promoter region, a number
of factors that control ABCA1 expression have been character-
ized. These include the transcription factor zinc finger protein
ZNF202, which appears to function as a major repressor of
ABCA1 transcription [45], oncostatin M [46] and geranylger-
anyl pyrophosphate which directly acts as an antagonist of
nuclear hormone receptor liver X receptor [47]. Importantly, the
in vitro demonstration that the peroxisome proliferator activated
receptors PPARα and PPARγ activators induce ABCA1
expression in macrophage-derived foam cells suggests the
involvement of nuclear receptors in the activation of the
ABCA1 pathway in these cells [48,49]. This is supported by
experiments in chimeric LDLR−/−mice lacking PPARγ in their
hematopoietic cells which show a significant increase in
atherosclerosis supporting the concept that PPARγ dependent
activation of macrophage ABCA1 expression is atheroprotec-
tive in vivo [49]. Next to PPARγ another nuclear receptor, liver
X receptor α, has also been implicated in sterol-dependent
transactivation of the ABCA1 promoter [50,51]. Based on these
findings, promising efforts have been initiated to identify drugs
targeting the PPARγ – liver X receptor – ABCA1 regulatory
circuit which can be used to therapeutically influence the
progression of atherosclerosis [52]. In this context, the recent
demonstration in LDLR−/− mice that atheroprotection mediat-
ed by PPARγ can also occur independently of ABCA1 suggests
that this receptor may exert its antiatherosclerotic effect through
more than one pathway [53].
Besides these well-established regulatory factors, available
evidence suggests critical roles for unsaturated fatty acids in the
control of ABCA1 activity. This is based on the observation that
unsaturated but not saturated fatty acids markedly inhibit
ABCA1 dependent cholesterol/phospholipid efflux from
macrophages [54]. Recent studies suggest that this effect is
likely the result of reduced ABCA1 gene expression [55] and
increased ABCA1 degradation [54]. The latter mechanism
appears to involve stearoyl-CoA desaturases and the PLD2
signaling pathway [56,57]. Because unsaturated fatty acids are
typically elevated in diabetes, increased levels of nonsaturated
lipids may significantly contribute to low HDL cholesterol in
patients with diabetes. Such a pathophysiological scenario
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cholesterol metabolism and diabetes.
3.2. ABCA3 and neonatal surfactant deficiency
After the initial discovery of ABCA1 and ABCA2, a third
homologous protein, designated ABCA3, was discovered in
1996 from a human medullary thyroid carcinoma cell line
[58,59]. ABCA3 encodes a 1704 amino acid protein of 190 kDa
size (Table 1) [60]. The ABCA3 gene is located on chromosome
16p13.3 in close proximity to the human homolog of the rodent
testis specific ABC transporter, AbcA17 (A. Piehler, unpub-
lished). ABCA3 shows highest expression in the lung but is also
expressed in brain, heart and pancreas. Ultrastructural studies
revealed that in the lung ABCA3 is expressed exclusively on the
limiting membranes of so-called lamellar bodies of alveolar
type II pneumocytes [60].
Pulmonary surfactant is a mixture of lipids, mostly
phospholipids, and proteins that is essential for normal
breathing. It forms a lipid-rich monolayer that coats the airways
of the lung and lowers surface tension at the air–liquid interface
thus preventing end-expiratory collapse of the alveoli. The
lipids and proteins that make up surfactant are assembled in
lamellar bodies from which they are secreted into the alveolar
space [61]. Selective expression of ABCA3 in lamellar bodies
early on pointed to its potential implication in surfactant
metabolism, a hypothesis that was supported by several other
observations. In the rat, ABCA3 mRNA expression is strongly
induced during lung development and highest ABCA3 mRNA
levels are found shortly before birth synchronously with the
transcriptional induction of the surfactant-associated proteins.
Further, in vitro incubation of human fetal lung explants with
dexamethasone results in a dramatic increase in ABCA3 mRNA
expression relative to controls [62]. This regulatory response
could also be observed on the protein level in rats [63]. The
ABCA3 promoter contains a functional glucocorticoid-respon-
sive element (GRE) as evidenced by the findings that
transcriptional activity mediated by the GRE containing region
shows a twofold increase in the human alveolar type II cell line
A549 in response to dexamethasone and specific binding of the
glucocorticoid receptor to the GRE could be demonstrated [63].
Based on these data, strongly suggesting roles for ABCA3 in
surfactant metabolism, Shulenin and colleagues [64] screened
21 ethnically diverse full-term newborns with fatal surfactant
deficiency for mutations in the ABCA3 gene. In these subjects
no known causes for the respiratory distress syndrome including
mutations in the surfactant protein B or C could be found.
Clinically, the onset of respiratory symptoms had occurred
shortly after birth and the majority of these infants died within a
month after birth. Histological sections of the lung showed the
picture of desquamative interstitial pneumonitis and/or pulmo-
nary alveolar proteinosis. A similar phenotype can be observed
in patients with mutations in the surfactant protein B [65]. In 16
of the 21 infants, mutations in the ABCA3 gene were found.
Genetic abnormalities include homozygous nonsense and
frameshift mutations, heterozygous insertions and splice-site
mutations, and also missense mutations in conserved aminoacid residues [64]. The demonstration that defects in the ABCA3
gene cause neonatal surfactant deficiency identifies this
transporter as a critical regulator of lung surfactant metabolism.
The detailed molecular mechanisms by which ABCA3 exerts its
function in pneumocytes are presently unknown. A potential
clue comes from the observation that patients with mutated
ABCA3 showed abnormal lamellar bodies in their lung tissue.
The lamellar bodies in these infants are small and tightly packed
with eccentrically positioned densely stained inclusions.
Mechanistically, it is thus likely that ABCA3 is directly
implicated in phospholipid translocation processes that are
critical for the proper formation of lamellar bodies and the
subsequent secretion of surfactant into alveoli.
Of note, not all individuals with mutations in the ABCA3
gene in this study died from respiratory failure suggesting that
mutations in this transporter are also associated with milder
forms of pediatric interstitial lung disease. To test this
possibility, ABCA3 mutation analysis was performed in a
cohort of children with chronic lung disease of unknown
etiology [66]. Intriguingly, in three out of four patients with the
histological diagnosis of desquamative interstitial peumonitis,
who were older than 10 years at the time of enrollment,
heterozygosity for a novel missense mutation (E292V) was
found. Heterozygosity for the E292V mutation was detected in
seven additional patients and in eight of the ten patients a
second, distinct mutation was identified on the other ABCA3
allele. These findings document that genetic variants in the
ABCA3 gene not only cause a neonatal phenotype associated
with severe surfactant deficiency but may also control
susceptibility to milder forms of interstitial lung disease.
3.3. ABCA4 (ABCR) and retinal dystrophies
ABCA4 (also known as ABCR or the rim protein) is a
retinal-specific member of the family of ABC transporters. It
was the first ABC A-transporter that has been causatively
linked to genetic disease [21,22]. It encodes a 2273 amino
acid full-size ABC transporter protein which is localized in the
retina along the rims and incisures of rod and cone
photoreceptor outer segment disk membranes [21,22,67,68].
Available evidence suggests that ABCA4 may act as an ATP
dependent flippase that translocates N-retinylidene-phosphati-
dylethanolamine (-PE) from the lumen to the cytoplasmic side
of the disk membrane. This action promotes the recycling of
all–trans retinal released from photobleached rhodopsin via
the retinoid cycle. It has thus been suggested that compro-
mised ABCA4 transporter activity may lead to the accumu-
lation of toxic all–trans retinal derivatives in rods and cones,
which results in apoptosis of the supporting retinal pigment
epithelium cells and, ultimately, degeneration of the photo-
receptors [69–71]. This view is in agreement with the recent
observation that ABCA4 indeed binds the retinoid N-retinyli-
dene-PE with high affinity [72]. To date >400 sequence
variations in the ABCA4 gene have been documented (for a
current synopsis see http://www.retina-international.org/sci-
news/abcrmut.htm) and linked to four degenerative retinal
diseases including Stargardt disease (STGD), cone-rod
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and age-related macular degeneration (AMD), respectively.
STGD is an autosomal recessive macular dystrophy causing
progressive impairment of central vision, which clinically
manifests typically in childhood or young adulthood. Affected
individuals display atrophic lesions in the macula, as well as
characteristic yellowish flecks in the macular and perimacular
region [73]. Allikmets et al. (1997) provided the first report
demonstrating that patients with STGD have mutations in their
ABCA4 gene [22]. Subsequent extensive mutation analyses
have confirmed that ABCA4 is the gene underlying STGD and
have initiated a characterization of the mutational spectrum
[74–79]. Interestingly, some mutant alleles such as G863A,
A1038V, and G1961E, respectively, appear to be more common
and may have altered frequencies in different populations,
presumably as a result of a founder effect [76,80].
Previous analyses of ABCA4 mutations in individuals with
STGD, AMD, CRD3, or RP19 led to the suggestion of a model
in which ABCA4 mutations can cause a spectrum of retinal
disease, with the clinical phenotype determined by the level of
residual ABCA4 protein activity (residual activity model)
[74,76,81,82]. For example, the homozygous frameshift
mutation 5917delG is associated with a relatively severe
STGD phenotype and the truncating mutations Y362X and
R1300X, respectively, are associated with milder clinical
symptoms [77,81]. Although, no direct assay for the assessment
of the transporter activity of ABCA4 is currently available, this
concept is supported by a series of indirect observations
including human genetics studies that correlate age of onset
and/or phenotypes conveyed by the selective combination of
mutant ABCA4 alleles [75,83]. Moreover, studies in Abca4
knockouts, which demonstrate that these null mutant mice
partially develop human retinal disease by manifesting the
accumulation of lipofuscin, delayed dark adaptation and slow
progression of photoreceptor degeneration support the recipro-
cal correlation between ABCA4 activity and clinical phenotype
[70,71,84,85]. Autosomal recessive retinitis pigmentosa 19 is
the most severe retinal dystrophy caused by mutations in the
ABCA4 gene and is believed to be caused by complete loss of
ABCA4 activity. Consistent with the residual activity model
truncating or aberrant splicing mutations are predominantly
found in families with RP19 [81,82,86].
AMD accounts for more than half of severe visual
impairment in studied populations of European descent, with
at least 1.7 million individuals affected in the USA [87].
According to the residual activity model, the mild end of the
ABCA4 associated phenotypic spectrum would be AMD,
resulting from either homozygosity for a very mild mutation or
heterozygosity for a moderate or severe alteration. Initially, an
association between AMD and heterozygous mutations in
ABCA4 has indeed been established [22]. This was supported
by the observation that the frequency of two common ABCA4
variants, G1961E and D2177N, in 1200 patients with AMD is
significantly higher (3.4%) than that of controls (0.95%) [88].
However, other studies could not confirm these results [77,89].
More recent reports in both humans and mice suggest that
ABCA4 is a dominant susceptibility locus for predisposition toAMD [84,87]. The controversial findings in the context of
AMD highlight the specific problems in the evaluation of the
pathogenetic relevance of mutations in large genes such as the
transporter ABCA4. It also emphasizes the need to take
environmental and additional hereditary factors into account
in the interpretation of mutation data sets associated with
ABCA4. Bearing in mind the fact that 7% of individuals age >75
years are affected with late-stage AMD [90] and an estimated
mutant ABCA4-heterozygote frequency of 2–3% in the general
population [22], in detail characterization of the pathogenetic
role of ABCA4 in AMDwill be a major challenge for the future.
3.4. Defective ABCA12 causes two congenital keratinization
disorders
ABCA12 was recently discovered in human placenta [91].
Four full-length cDNAs were identified that contain two
different polyadenylation sites and two splice variants coding
for two distinct ABCA12 isoforms of 2595 and 2516 aa size,
respectively [91]. ABCA12 shares significant amino acid
sequence homology with ABCA1 (36%), ABCA7 (36%) and
ABCA3 (35%). RT-PCR experiments revealed highest expres-
sion levels in skin, testis and fetal brain [91]. The gene is
composed of 53 exons and maps to chromosome 2q34, a region
that harbors, among others, a locus for the keratinization
disorder lamellar ichthyosis [92] identifying ABCA12 is a
positional candidate for this hereditary skin disease.
Indeed, Lefevre et al. [93] found missense mutations in the
ABCA12 gene in nine African families with lamellar
ichthyosis type 2, an autosomal recessive form of ichthyosis
which is characterized by skin desquamation over the whole
body with large, adherent, pigmented and dark scales. The
mutations were homozygous in 8 consanguineous families
and heterozygous in one non-consanguineous family. Four of
the missense mutations were located in the highly conserved
first ATP-binding cassette, which is essential for the integrity
of ABC transporter function. Two recent independent studies
demonstrated that mutations in the ABCA12 gene also
underlie another keratinization disorder-harlequin ichthyosis
[94,95]. The majority of the patients suffering from this
disease was homozygous or compound heterozygous for
mutations (deletions, insertions or splice junction mutations)
that completely altered the amino acid sequence of the protein
or resulted in the deletion of amino acid residues in highly
conserved domains suggesting a complete disruption of the
protein function. These findings indicate that the nature and
severity of mutations in the ABCA12 gene account for two
clinical phenotypes: a severe one presenting as harlequin
ichthyosis and a milder form manifesting as lamellar
ichthyosis type 2.
Harlequin ichthyosis is the most severe form of congenital
ichthyosis [96,97]. It is characterized by a profound
thickening of the keratin layer in fetal skin. Affected neonates
are born with a massive horny shell of dense platelike scale
and contraction abnormalities of the eyes, the ears, the mouth,
and the appendages. This “armor” limits movement and
compromises the protective skin barrier leading to excessive
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tion, and increased risk of life-threatening infection. Affected
babies mostly die within a few days after birth because of
feeding complications, respiratory distress and severe infec-
tions. The term harlequin derives from the newborn's facial
expression and the triangular and diamond-shaped pattern of
hyperkeratosis.
During normal keratinocyte differentiation, lipids accumu-
late in so-called lamellar granules (LG) which are subsequent-
ly extruded into the intercellular spaces where they undergo
enzymatic processing to produce a lipid mixture consisting of
ceramides, cholesterol and fatty acids [98]. This lipid complex
fills most of the intercellular space of the stratum corneum
forming the water permeability barrier of the skin. Immuno-
histochemistry demonstrated that ABCA12 is present in the
upper epidermal layers of normal human skin and immunoe-
lectron microscopic localization studies revealed its exclusive
presence in LG of normal epidermal keratinocytes [95]. LG
are specialized lipid-rich organelles characteristically found in
epidermal granular cells. ABCA12 containing LG were
abundantly detected close to the cell membrane where they
fused with the cell membrane to secrete their lipid content to
the extracellular space of the stratum corneum. These
observations clearly show expression of ABCA12 in kerati-
nocytes during keratinization and they suggest its implication
in the LG dependent lipid export pathway. The lipid
compounds whose translocation is mediated by ABCA12 are
unknown. Ultrastructurally, harlequin ichthyosis is character-
ized by abnormal or absent lamellar granules [96] indicating
that the assembly of these lipid-rich organelles is perturbed in
the absence of functional ABCA12. Furthermore, cultured
keratinocytes of harlequin ichthyosis patients exhibit a
congested pattern of glucosylcermide, a major lipid compo-
nent of LG, around the nuclei compared to healthy
keratinocytes. Corrective ABCA12 gene transfer into
ABCA12 deficient keratinocytes increased the number of
keratinocytes showing the diffuse glucoceramide staining
present in healthy keratinocytes [95]. These data together
with the known colocalization of ABCA12 and LG strongly
suggest that ABCA12 is implicated in intracellular transloca-
tion processes of sphingolipids that are required for maintain-
ing the integrity of lamellar granules.
It should be pointed out that the A-subclass transporters
ABCA12 and ABCA3 have in common that they are exclusively
localized in a secretory intracellular lipid storage compartment,
i.e., lamellar granules in keratinocytes and lamellar bodies in
pneumocytes, respectively [60,95]. It is thus tempting to
speculate that both transporters evolved from the same
primordial lipid export system during the development of the
respiratory system and the integument at the time when
vertebrates left the aquatic environment.
4. Potential disease causing ABC A-subfamily members
Given the association of the ABC A-transporters ABCA1,
ABCA3, ABCA4 and ABCA12 with genetic diseases, it is
almost predictable that other members of this subfamily mayalso underlie hereditary disorders. This group of potential
candidate genes includes ABCA2, the ABCA6-like cluster
(ABCA5, ABCA8, ABCA9, ABCA10) and ABCA13, respectively.
4.1. ABCA2
ABCA2 was originally co-identified with ABCA1 in mice
[10]. The human gene was cloned in 2001 by our laboratory [99]
and also by another group [100]. The ABCA2 full-length cDNA
is 7.3 kb in size and codes for a 2436 amino acid polypeptide
with a calculated molecular weight of ∼270 kDa (Table 1).
Genomic analysis identified a total of 48 exons extending across
a genomic region of only 21 kb on chromosome 9q34 [99]. The
majority of introns are less than 0.3 kb in size which accounts for
the unusually compact genomic organization. Recently, an
additional 5′ exon was identified encoding an alternative unique
N-terminus with highest expression in lysosomal compartments
of peripheral blood leukocytes [101]. Amino acid sequence
homology analysis places ABCA2 into the same evolutionary
subgroup as ABCA1, ABCA3, ABCA4 and ABCA7, respec-
tively (Fig. 1). Expression profiling showed highest levels of
ABCA2 mRNA levels in the brain, however, expression was
also detected in a broad range of tissues including monocytes,
macrophages, kidney, liver, thymus, heart, ovary, lung and
various tumor cells [10,99–103]. Using a semiquantitative RT-
PCR approach, we demonstrated sterol-sensitive regulation of
the ABCA2 gene in human macrophages suggesting a role for
this transporter in monocyte/macrophage lipid metabolism [99].
Analysis of the putative ABCA2 promoter region revealed
several potential binding sites for transcription factors with
functions in myeloid and neural cell differentiation and
activation [104]. Luciferase reporter gene experiments showed
the importance of two GC-rich regions and overlapping binding
sites for the EGR-1 and Sp1 transcription factors in the control of
ABCA2 gene expression [105].
Although the ABCA2 gene has been described almost a
decade ago, little is known about its function. Overexpression of
a GFP-tagged ABCA2 chimeric protein revealed that ABCA2
localizes to the endolysosomal compartment and the Golgi
apparatus [100] which is consistent with another study
demonstrating the presence of ABCA2 in the endolysosomal
compartment of rat oligodendrocytes [103]. Two studies which
report resistance of ABCA2 overexpressing HEK293 cells to
the estrogen-based antitumor drug estramustine and an
association of increased ABCA2 expression with resistance to
the chemotherapeutic agent mitoxantrone in a small cell lung
cancer cell line suggest the implication of ABCA2 in multidrug
resistance [100,106]. At this point, the clinical implications of
these findings remain unclear. Given its localization in the
lysosome, ABCA2 may facilitate the transport of cytotoxic
compounds from the cytoplasm to the lysosomal compartment
for detoxification. It needs to be cautioned, however, that the
extrusion of xenobiotics, a common feature of many ABC
transporters, is not necessarily related to the bona fide
physiological function of ABCA2.
Taken together, the high expression levels in the brain, the
localization in oligodendrocytes and sterol-sensitive regulation
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transport. In line with this view, transfection experiments
demonstrate that ABCA2 expression levels influence the
expression of a number of genes linked to Alzheimer's disease
(AD) including amyloid β precursor protein (chromosome
21q21.3) whose pathogenetic role in AD is well established
[107]. Other authors noted an association between early onset
AD and the synonymous SNP rs908832 in exon 14 of the
ABCA2 coding region [108]. However, more extensive studies
are required to corroborate such an association, in particular
because the ABCA2 polypeptide structure is not affected by the
silent C/T variant. More importantly, several hereditary
neurological disorders have been linked to the ABCA2 locus
on chromosome 9q34 including amyotrophic lateral sclerosis 4
(OMIM 602433), the lethal congenital contraction syndrome
(OMIM 253310), autosomal recessive deafness 33 (OMIM
607239) and Joubert syndrome, a pathology associated with
hypoplasia of the cerebellar vermis (OMIM 213300). ABCA2 is
thus a promising positional candidate gene for these neurolog-
ical diseases.
4.2. ABCA6-like transporters
Five closely related members of the human ABC A-
subfamily form a compact gene cluster on chromosome
17q24.2–3 comprising the genes for ABCA5, ABCA10,
ABCA6, ABCA9 and ABCA8 (in that order). This genomic
organization is unique among human ABC transporters. Their
common chromosomal location of the ABCA6-like transpor-
ters and their strikingly high overall peptide sequence
identities, ranging from 42 to 72% (Fig. 1, Table 2), strongly
support the hypothesis that these transporters evolved from a
common ancestral gene [1,11]. Because the human ABCA6
gene was the first to be characterized in completeness [109],
the members of the ABC A-transporter pentacluster have been
referred to as “ABCA6-like transporters” [11]. With the
exception of ABCA10, all ABCA6-like transporters are
found in the rodent genome suggesting that the initial
duplication events have taken place before the divergence of
the rodent and primate lineages. Phylogenetic analysis suggests
that ABCA5 is the oldest gene in the ABCA6-like transporter
gene cluster and the other members are the result of a cascade
of duplication events (see Fig. 1). The recent observation that
the Fugu rubripes genome has only one ortholog of the cluster
(ABCA5) supports this view and chronologically positions the
expansion of the ABCA6-like transporter genes after the split
of the teleost lineage [12].
Historically, ABCA8 was the first human ABCA6-like
transporter to be cloned [110], followed by ABCA6, ABCA9,
ABCA5 and ABCA10, respectively, which were identified by our
laboratory and others during the past years [11,109,111,112].
The defining member ABCA6, a polypeptide of 1617 amino
acids, bears the structural features of full-size transporters,
however, like all other ABCA6-like transporters, it is
significantly smaller in size than ABC A-transporters outside
this subgroup (Table 1). ABCA6-like transporters generally
show a broad tissue-specific distribution with individualquantitative expression profiles. Typically, at least one alterna-
tive mRNA variant exists for each ABCA6-like transporter
mostly coding for truncated hypothetical protein products
(Table 1) [11,109,111,112].
The biological significance of ABCA6-like transporters is
unclear. The finding that the genes for ABCA6, ABCA9 and
ABCA10 are regulated by cholesterol in human macrophages
points to their potential involvement in lipid transport processes
in these cells. Of importance may be the fact that these
ABCA6-like transporters display regulatory profiles that are
consistently reciprocal to those of ABCA1, ABCA2, and
ABCA7, respectively [11,109,112] raising the possibility that
both transporter groups may (in part) exert antagonistic
functions in macrophages. An important clue to possible in
vivo functions of ABCA6-like transporters comes from most
recent murine experiments demonstrating that ABCA5 is
localized in the endolysosomal compartment and Abca5
deficient mice develop a dilated heart reminiscent of dilatative
cardiomyopathy leading to fatal cardiac failure [113]. Abca5
knockouts also exhibit exophthalmos and a collapse of the
thyroid gland. Collectively, the observed abnormalities in
cardiomyocytes and follicular cells are consistent with the view
that Abca5 may serve critical functions in the endolysosomal
system. It will be fascinating to investigate whether mutations
in the ABCA5 gene cause an equivalent of this murine
phenotype that exists in human pathology.
4.3. ABCA7
The A-subfamily transporter ABCA7 was initially cloned
from human macrophages in which it is subject to regulation
by cholesterol influx and efflux [20]. The ABCA7 cDNA is of
6.8 kb size encoding a polypeptide of 2146 amino acids with a
calculated molecular weight of 220 kDa which exhibits
highest protein sequence homology with ABCA1 (54%) and
ABCR (49%) [20,114]. ABCA7 is predominantly expressed in
myelo-lymphatic tissues with highest expression in peripheral
leukocytes, thymus, spleen, and bone marrow, but also in
platelets and keratinocytes [20,115,116]. The ABCA7 gene
consists of 46 small exons which are separated by relatively
small intron sequences [117] and several alternative mRNA
variants have been identified (W. Kaminski, unpublished). The
molecular function of ABCA7 is a currently unresolved issue.
Overexpression experiments in human HeLa and HEK293
cells suggest that ABCA7 is implicated in the regulation of
ceramide and phospholipid export from the cell but not of
cholesterol [115,118], whereas other data demonstrate in-
creased efflux of both cholesterol and phospholipids in
ABCA7 transfected HEK293 cells [119]. Current data on the
subcellular localization of ABCA7 are also confusing. Initial
experiments in ABCA7 overexpressing HEK293 cells indi-
cated its presence in the plasma membrane [118] which
contrasts with the recent finding, by the same group, that
ABCA7 is predominantly localized intracellularly but not at
the plasma membrane in mouse peritoneal macrophages [120].
The situation is complicated by studies in Abca7 null mice
whose macrophages were found to have normal cholesterol
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able function of Abca7 in the cholesterol/phospholipid export
in the mouse. Intriguingly, the Abca7 knockout approach
revealed a gender dependent reduction in visceral fat and
serum cholesterol levels. It remains to be established whether
these unexpected observations are a species-specific physio-
logical characteristic of mice or whether they represent
important clues to as yet unsuspected roles of ABCA7 in
human lipid metabolism.
Interestingly, the ABCA7 gene is intimately physically
linked to the gene for the minor histocompatibility antigen
HA-1 on chromosome 19p13.3. Both genes are arranged in
a head-to-tail array with only 1.7 kb distance between the
terminal exon of ABCA7 and the initial exon of the HA-1
gene [117]. It thus cannot be entirely ruled out that the
ABCA7 and HA-1 genes overlap raising the possibility that a
functional and regulatory interlink exists between both
genes. HA-1 is a cytosolic protein of 1165 amino acid
size [110] and unknown function. An H168R polymorphism
in the HA-1 polypeptide sequence has been identified as the
immunologic target for HA-1 specific cytotoxic T cells
[122]. Available information suggests that ABCA7/HA-1
may be involved in autoimmune disease. On the one hand,
this is based on the fact that both genes are expressed in
macrophages and lymphocytes, major effector cells in
chronic inflammation. On the other hand, database search
in our laboratory revealed that a polypeptide of app. 150
amino acids length within the first extracellular domain of
ABCA7 is recognized by antisera from Sjögren's syndrome
patients (“Sjögren epitope”) suggesting that ABCA7 is
associated with the pathogenesis of this autoimmune disease.
A recent study demonstrated no association between allelic
variants of the ABCA7 gene and Sjögren's syndrome,
however, it revealed that the 168H variant of the minor
histocompatibility antigen HA-1 is associated with reduced
risk of primary Sjögren's syndrome [123]. That these results
do not entirely exclude the potential involvement of ABCA7
in Sjögren's syndrome is evidenced by recent work
reporting that ABCA7 is expressed in salivary glands of
patients with Sjögren's syndrome [124]. Further efforts are
required to assess the role of the ABCA7/HA-1 gene
complex in Sjögren's syndrome and also in other autoim-
mune disorders.
4.4. ABCA13
ABCA13 is by far the largest ABC transporter with a
molecular mass of app. 576 kDa [125]. The full-length
transcript cloned from lung RNA comprises 17209 bp with an
open reading frame of 15195 bp and five additional alterna-
tively spliced mRNA variants have been identified presumably
encoding truncated isoforms of the canonical ABCA13 protein
[125]. Interestingly, the cDNA of three transcript variants
contain a second open reading frame at the 5′ end coding for an
unrelated hypothetical protein of 717 aa size. The human
ABCA13 gene is located on chromosome 7p12.3 and consists of
62 exons. The predicted ABCA13 polypeptide stands outamong all human ABC A-transporters in that the N-terminal
extracellular loop consists of more than 3500 aa. This
hydrophilic domain is conserved in the mouse, but no
significant homology to any other protein domain could be
identified so far. ABCA13 displays highest amino acid
sequence identity with ABCA12 (38%), ABCA1 (36%) and
ABCA7 (36%), respectively (Table 2). In normal tissues,
highest mRNA expression of the ABCA13 full-length mRNA
was found in human trachea, testis and bone marrow.
Expression profiling in tumor cell lines showed highest
mRNA levels in leukemia, brain and prostate tumor cell lines,
respectively [125]. Presently, little is known about the role of
ABCA13 in physiology and disease. ABCA13 shares a common
genomic region on chromosome 7p12.3 with the locus linked to
the T-cell tumor invasion and metastasis, INM7 [125].
Interestingly, several potential binding sites for transcription
factors associated with hematopoiesis of the myeloid and
lymphoid lineages have been identified in the murine ABCA13
promoter [126]. Together, these results and the high expression
levels in leukemic cell lines, render ABCA13 a possible
candidate player in hemato-oncological pathologies.
5. Conclusions
Significant evidence has accumulated during the past years
to support the concept that ABC A-subfamily transporters serve
critical functions in human physiology which, when they are
defective, cause disease. Currently, available data allow us to
begin to outline what may be characteristic features of these
transporter molecules. One of the emerging key features is that
they appear to function as complex and highly specialized
transport platforms that mediate the translocation of physiologic
lipid compounds across biological membranes. Known or
potential substrates of ABC A-transporters include phospholi-
pids (ABCA1, ABCA3, ABCA4, ABCA7), cholesterol
(ABCA1) and sphingolipids (ABCA12). As with other human
ABC proteins, we still await clarification on how ABC A-
subclass transporters mediate the translocation of their specific
substrates on a molecular level. This task is complicated by a
growing body of evidence suggesting that ABC transporters do
not act alone but rather function as components of molecular
multi-unit complexes. In the case of ABCA1, such a
translocator complex, which controls the cellular export of
cholesterol and phospholipids, may include β1- and β2-
syntrophin, utrophin and phospholipid transfer protein as its
molecular constituents [39,40,127,128].
The most important lesson that we have thus far learned
about human ABC A-transporters comes from mutation
analyses. The still limited number of studies revealed a
broad spectrum of both mutations and clinical phenotypes for
each ABC A-protein that has been causatively linked to
disease. This pleiotropism has been documented most
convincingly for the transporter ABCA4 (ABCR), for which
more than 400 mutations have been reported to date which,
altogether, give rise to a wide range of clinical manifestations.
Future studies will help to determine whether a similar extent
of genotype/phenotype diversity also exists for other ABC A-
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discovered disease-causing genes, ABCA3 and ABCA12,
which have not yet received the same longstanding scientific
attention as ABCA4. The genotype/phenotype diversity in
individuals with mutated ABC transporters may primarily
reflect the functional complexity of these large multispan
polypeptides. However, because ABC transporters likely exert
their biological function in cooperation with possibly varying
interaction partners, it should be taken into account that the
observed range of clinical phenotypes associated with
mutations in one and the same ABC molecule may also
reflect genetic variations of proteins that specifically interact
with ABC transporters.
Despite our still rudimentary knowledge on the biology of A-
subclass ABC transporters, it becomes increasingly clear that
each member of this protein family has adopted a distinct and
highly specialized physiological function throughout evolution.
The evolutionary radiation of the transporters of the A-
subfamily is a most impressive paradigm for how modifications
of one and the same biological principle can generate an
enormous degree of functional diversity. It will be a major
challenge for the future to elucidate in detail the workings of this
fascinating group of proteins and expand our knowledge of their
implication in human pathologies.
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